IP Verse

Boehringer Ingelheim International Gmbh competitive analysis

Latest oppositions filed by Boehringer Ingelheim International Gmbh

Explore patent oppositions filed by Boehringer Ingelheim International Gmbh against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Aug 20, 2026
Patent NumberTitleApplicantOpposition Date
EP3165600
Cell Culture Medium Comprising Small PeptidesLIFEAug 1, 2023
EP3874047
Carbon-Source Regulated Protein Production In A Recombinant Host CellLONZAJan 9, 2023
EP3342786
Anti-Dll3 AntibodyCHUGAI SEIYAKU KABUSHIKI KAISHAMar 22, 2022
EP3541387
Dose And Regimen For Hdm2-P53 Interaction InhibitorsNOVARTISJan 20, 2022
EP3177645
Subcutaneously Administered Bispecific Antibodies For Use In The Treatment Of CancerLINDHOFERNov 16, 2021
EP3160463
Intermittent Dosing Of Mdm2 InhibitorNOVARTISJul 16, 2021
EP2820151
Cancer Patient Selection For Administration Of Wnt Signaling Inhibitors Using Rnf43 Mutation StatusIRMDec 15, 2020
EP2847223
Anti-B7-H6 Antibody, Fusion Proteins, And Methods Of Using The SameTRUSTEES OF DARTMOUTH COLLEGEDec 20, 2019
EP2647707
Cytotoxicity-Inducing Therapeutic AgentCHUGAI SEIYAKU KABUSHIKI KAISHAJun 12, 2019
EP2530091
Anti-Dll3 AntibodyCHUGAI SEIYAKU KABUSHIKI KAISHAJan 2, 2019

Latest patents of Boehringer Ingelheim International Gmbh opposed by its competitors

Explore Boehringer Ingelheim International Gmbh's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 20, 2026
Patent NumberPublication DateTitleTotal Oppositions
EP2396005
Nov 26, 2025Sglt-2 Inhibitor For Treating Type 1 Diabetes Mellitus, Type 2 Diabete Mellitus, Impaired Glucose Tolerance Or Hyperglycemia5
EP3700529
Jul 9, 2025New Combination Of Active Agents For The Treatment Of Progressive Fibrosing Interstitial Lung Diseases (Pf-Ild)2
EP4426307
Jul 2, 2025New Oral Pharmaceutical Composition And Dose Regimen For The Therapy Of Progressive Fibrosing Interstitial Lung Diseases2
EP3826642
Jun 11, 2025Empagliflozin For Use In Treating Alport Syndrome1
EP2152341
Apr 2, 2025Atomizer, And Filter2
EP3453403
Jan 22, 2025Dpp-Iv Inhibitor Combined With A Further Antidiabetic Agent, Tablets Comprising Such Formulations, Their Use And Process For Their Preparation1
EP3539540
Dec 18, 2024Pharmaceutical Composition, Methods For Treating And Uses Thereof11
EP3150200
Apr 10, 2024Pharmaceutical Composition, Pharmaceutical Dosage Form, Process For Their Preparation, Methods For Treating And Uses Thereof4
EP2395968
Jan 17, 2024Pharmaceutical Composition Comprising Glucopyranosyl Diphenylmethane Derivatives, Pharmaceutical Dosage Form Thereof, Process For Their Preparation And Uses Thereof For Improved Glycemic Control In A Patient19
EP2313087
Nov 22, 2023Pharmaceutical Dosage Form For Immediate Release Of An Indolinone Derivative3

Latest PTAB cases involving Boehringer Ingelheim International Gmbh

Discover the latest PTAB cases involving Boehringer Ingelheim International Gmbh, highlighting their recent legal challenges and patent disputes.

Last updated on: Aug 19, 2026
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Boehringer Ingelheim International Gmbh

PGR2022-00037May 2, 2022SANDOZBOEHRINGER INGELHEIMInstitution Denied
IPR2016-00408Dec 29, 2015BOEHRINGER INGELHEIMABBVIE BIOTECHNOLOGYFinal Written Decision
IPR2016-00409Dec 29, 2015BOEHRINGER INGELHEIMABBVIE BIOTECHNOLOGYFinal Written Decision

Peer Comparison New

IP litigation analysis comparing Boehringer Ingelheim International Gmbh with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Aug 20, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
BOEHRINGER INGELHEIM3418889